HPV vaccine acceptability mean† | Author(s) | Population | Age (range, mean) | Sexual orientation/behaviour‡ (%) | Sample size | Country | Risk of Bias |
---|---|---|---|---|---|---|---|
94.0 | Rand et al29 | Adolescents | 15–17, M=N/R | N/R | 22 | USA | High |
93.6§ | Daley et al30; Daley et al31 | Adults | 18–70, M=27.8 | N/R | 296 | USA | High |
77.5 | Jones et al45 | College students | 18–32, M=N/R | N/R | 138 | USA | High |
74.3 | Gottvall et al43 | Adolescents | 14–19, M=16.0 | N/R | 608 | Sweden | High |
74.0 | Gilbert et al32; Gilbert et al33; McRee et al48; Reiter et al51 | Adults | 18–59, M=N/R | Gay/bisexual | 306 | USA | Moderate |
71.5¶ | Hernandez et al44 | Adults | 18–79, M=N/R | MSM (20.0%); heterosexual (80.0%) | 445 | USA | High |
70.8 | Petrovic et al35 | Adults | 18–26, M=22.3 | N/R | 121 | Australia | High |
68.8 | Bynum et al38 | College students | N/R, M=20.6 | Heterosexual (91.1%); Gay/bisexual/unsure (4.5%); Unknown (4.5%) | 575 | USA | High |
65.8 | Chelimo et al39 | College students | N/R, M=19.8 | N/R | 38 | New Zealand | High |
65.5 | Gerend et al42 | College students | 18–24, M=18.8 | Heterosexual | 356 | USA | Low |
64.4 | Thomas et al55 | Adults | 22–56, M=36.6 | MSM | 191 | USA | High |
62.0 | Daley et al30; Daley et al31 | College students | 18–22, M=N/R | N/R | 198 | USA | High |
55.4 | Oh et al49 | Adults | N/R, M=53.1** | N/R | 496 | South Korea | High |
48.0 | Lenselink et al46 | College students | 18–25, M=19.8 | N/R | 223 | Netherlands | High |
47.3 | Marshall et al47 | Adults | N/R, M=N/R | N/R | 852 | Australia | High |
47.0 | Simatherai et al53 | Adults | 19–71, M=27.0** | MSM (100.0%) | 200 | Australia | High |
45.3 | Crosby et al40 | College students | 18–24, M=20.2 | History of same-sex experience (6.1%); No same-sex experience (93.9%) | 148 | USA | High |
37.0 | Reiter et al9; Gilbert et al32; Gilbert et al33; McRee et al48 | Heterosexual men | 18–59, M=N/R | Heterosexual | 297 | USA | Moderate |
36.0 | Wheldon et al34 | Adults | 18–29, M=21.6 | Gay/bisexual | 179 | USA | High |
34.3†† | Sundstrom et al54 | Adults | 18–30, M=23** | MSM, heterosexual | 1712 | Sweden | High |
33.0 | Ferris et al24; Ferris et al41 | Adults | 18–45, M=N/R | Heterosexual (95.4%), Gay/bisexual (4.6%) | 571 | USA | High |
28.9†† | Young et al36 | Adults | 18–31, M=21.2 | N/R | 143 | Philippines | High |
8.2 | Blodt et al37 | Vocational students | 18–25, M=N/R | N/R | 245 | Germany | High |
N/R | Pitts et al50 | Adults | 18–54, M=34.8 | N/R | 930 | Singapore | High |
N/R | Sauvageau et al52 | Adults | 18–69, M=44.8 | N/R | 154 | Canada | High |
Mean acceptability 56.64 (SD 21.32; median=62.0; SEM 4.45; 95% CI 47.42 to 65.86); N=8360 (22 studies); Range: 8.2–94.0.
Weighted mean acceptability: 50.43 (SD 21.49).
*Twenty-three unique samples were included in calculation of overall mean acceptability.
†Acceptability on a 0–100 point scale.
‡Mean acceptability across race/ethnicity.
§Sexual orientation or behaviour, as reported by authors.
¶Mean acceptability across sexual orientation.
**Median.
††Mean acceptability for vaccines with different costs.
MSM, men who have sex with men; N/R, Not reported.